Duration of Amitriptyline for Migraine Prophylaxis
After achieving migraine control with amitriptyline, continue treatment for 6 to 12 months, then attempt to taper and discontinue the medication. 1, 2
Treatment Timeline
Initial Trial Period
- Allow 2 to 3 months to assess treatment efficacy before determining success or failure 1, 2
- Clinical benefit may take this long to become fully apparent, so patience during the initial phase is essential
- Start at a low dose (typically 10 mg daily) and titrate gradually to 30-150 mg daily based on response and tolerability 1, 2
Maintenance Duration
Once successful migraine control is achieved, continue amitriptyline for 6 to 12 months before attempting to reduce or discontinue 1, 3, 4. This duration is recommended to:
- Minimize the possibility of relapse 5
- Ensure sustained benefit from the prophylactic effect
- Allow time for any underlying migraine patterns to stabilize
Tapering Strategy
After the 6-12 month maintenance period:
- Gradually reduce the dose rather than abrupt discontinuation 1
- Aim to find the minimum effective dose or completely discontinue if possible 4
- Monitor headache frequency during taper using a headache diary to detect early relapse
Key Clinical Considerations
When to Continue Beyond 12 Months
While guidelines recommend attempting discontinuation after 6-12 months, some patients may require longer treatment if:
- Migraines promptly recur during tapering attempts
- The patient has severe, disabling attacks that dramatically improved with treatment
- There are no significant adverse effects limiting long-term use
Monitoring During Treatment
- Have patients maintain a headache diary throughout treatment to objectively track attack frequency, severity, and disability 2
- This documentation helps determine when adequate control is achieved and guides decisions about tapering
Common Pitfall to Avoid
Do not discontinue amitriptyline prematurely (before 2-3 months) due to perceived lack of efficacy. The full prophylactic effect develops gradually, and early discontinuation may miss the therapeutic window 1.
Realistic Expectations
Amitriptyline can reduce migraine frequency by 50% in approximately half of treated patients 3. The moderate efficacy means some patients will need to try alternative prophylactic agents if adequate response is not achieved during the 2-3 month trial period 1, 2.
The 2025 ACP guidelines 6 emphasize that there is uncertainty about optimal discontinuation timing, but the consensus from multiple earlier guidelines consistently supports the 6-12 month maintenance approach followed by attempted taper.